

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) OCTOBER 19, 1995 ENZON,
INC.

(Exact name of registrant as specified in its charter)

DELAWARE (State or other jurisdiction of incorporation)	0-12957 (Commission File Number)	22-237286 (IRS Employer Identification)
---	--	---

20 KINGSBRIDGE ROAD, PISCATAWAY, NEW JERSEY (Address of principal executive offices)	08854 (Zip Code)
---	---------------------

Registrant's telephone number, including area code (908) 980-4500

(Former name or former address, if changed since last report)

ITEM 5. OTHER EVENTS

Enzon, Inc. ("Enzon" or the "Company") has been advised by Sanofi Winthrop, Inc. that the Phase III clinical trial of DISMUTEC<trademark> (pegorgotein) in patients with severe closed head injury has been evaluated and fails to show a statistically significant difference between the treatment group and the control group. DISMUTEC, the enzyme superoxide dismutase modified with Enzon's proprietary PEG-technology, is designed to decrease tissue injury caused by ischemia or trauma in severe closed head injury patients. Through modification with Enzon's PEG-technology, DISMUTEC exhibited longer circulating half-life and reduced immunogenicity; however, the drug showed insufficient therapeutic effect for this indication. The Company believes the results of the clinical trial have no immediate impact on the Company from an earnings or cash flow perspective and that these results do not reflect adversely on the Company's other products or PEG-technology.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: October 20, 1995

ENZON, INC.
(Registrant)

By: /S/ KENNETH J. ZUERBLIS Kenneth J. Zuerblis
Vice President, Finance
(Principal Financial and
Accounting Officer)